trending Market Intelligence /marketintelligence/en/news-insights/trending/YJv6ArxNkJGhxu7-VSSvLg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Bausch, Teva Pharmaceuticals settle patent dispute over colitis drug Apriso

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Bausch, Teva Pharmaceuticals settle patent dispute over colitis drug Apriso

Bausch Health Companies Inc. and its Salix Pharmaceuticals Ltd. unit agreed with Teva Pharmaceuticals USA Inc. to resolve litigation relating to the extended-release formulation of Apriso.

Apriso, or mesalamine, is used to treat inflammatory bowel disease ulcerative colitis in adults.

As part of the agreement, Bausch will grant Teva a nonexclusive license to market a generic version of the drug in the U.S., starting Oct. 1, 2021, and it will not make any financial payments or other transfers.

The patent for Apriso is set to expire in 2030.

Bausch, which acquired the rights to Apriso through its acquisition of Salix in April 2015, said it will continue to vigorously defend its intellectual property.

Bausch also modified its prior sub-license agreement for the drug with Lupin Pharmaceuticals Inc.